A. Legal Requirement, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA
Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 [Statutory Instrument 2004/1031], as amended by Statutory Instrument 2006/1928, contains a requirement for the notification of “serious breaches” of GCP or the trial protocol:
“29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of –
(a) the conditions and principles of GCP in connection with that trial; or
(b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.
(2) For the purposes of this regulation, a “serious breach” is a breach which is likely to effect to a significant degree –
(a) the safety or physical or mental integrity of the subjects of the trial; or
(b) the scientific value of the trial”.
Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
Предстоящие клинические испытания
-
University of Novi SadРекрутингОстрое повреждение почекСербия
-
The First Affiliated Hospital of Zhejiang Chinese...РекрутингВоспалительная реакция | Синдром Туретта у детей | Пищевая непереносимостьКитай
-
University of Rome G. MarconiUniversity of Bologna; University of the Italian SwitzerlandЕще не набираютСтресс | Бессонница | Послеродовая депрессияИталия
-
Selcuk UniversityЕще не набираютГеймификация | Студенты-медсестры | Multiple Intelligence Theory | Disaster NursingТурция
-
NuvoAir Medical PCOptum, Inc.Еще не набираютХОБЛ | ХОБЛ Обострение | Кардио/Пульм: сердечная недостаточность
-
Regeneron PharmaceuticalsIntellia TherapeuticsЕще не набирают
-
Centro di Riferimento Oncologico - AvianoРекрутингМетастатический немелкоклеточный рак легкого | Мутация гена ALKИталия
-
Omphis FoundationРекрутинг
-
Institut de cancérologie Strasbourg EuropeContinuum Plus Santé; Plateforme nationale qualité de vie et cancer; WeShareЕще не набираютНовообразования молочной железы | Новообразования легких | Новообразования предстательной железы | Колоректальные новообразованияФранция
-
Al-Balqa Applied UniversityLuzmila HospitalЕще не набирают
-
Musculoskeletal Injury Rehabilitation Research...The Geneva Foundation; Uniformed Services University (USU) of the Health Sciences; 1st... и другие соавторыЕще не набираютНизкоинтенсивная лазерная терапия | Фотобиомодуляционная терапия | Повышение производительности | Фотомедицина | Квадрицепсы | Готовность к специальным операциям
-
The Seventh Affiliated Hospital of Sun Yat-sen...Huizhou Municipal Central Hospital; Dongguan Hospital of Traditional Chinese Medicine и другие соавторыРекрутингОстеопороз Перелом | Компрессионный перелом | Остеопороз позвоночника | Выполнение лечения PVP/PKPКитай